Evaluation and management of cardiovascular disease and metabolic syndrome in pediatric-adolescent patients with psoriasis

Abstract

Psoriasis is strongly associated with cardiovascular disease (CVD) and metabolic syndrome, with pediatric and adolescent patients having an increased risk of each compared to the general population. This increased risk is based on shared underlying genetic and cytokine profiles, as well as similar environmental risks. Many screening guidelines do not address the development of CVD and metabolic syndrome in these predisposed patients, particularly in the adolescent population. These deficits are evidenced by the absence of validated 10-year CVD risk calculators for pediatric and adolescent patients with chronic inflammatory diseases, as well as insufficient screening guidelines for insulin resistance in patients with psoriasis. This manuscript aims to contribute literature regarding allopathic and lifestyle recommendations to the most recent 2017 consensus guideline for the pediatric/adolescent population with psoriasis. PubMed, COCHRANE Database of Systematic Reviews and Google Scholar were reviewed by a panel of clinicians with clinical and research expertise in psoriasis and pediatric subspecialties. The patient-centered Strength of Recommendation Taxonomy (SORT) method was utilized to grade the quality of the evidence available. Updates in management surrounding the role of lipoprotein(a) in lipid panels, recommendations for exercise and weight management to decrease insulin resistance, as well as guidance for heart rate and blood pressure management were discussed. Screening and managing pediatric and adolescent patients with psoriasis for the associated comorbidities of CVD and metabolic syndrome is imperative. Future high-quality studies are needed to strengthen the evidence provided throughout this review, which acts as a framework for clinical practice. Key words: Psoriasis, Comorbidity, Exercise, Treatment, Coronary heart disease